Reach - Non-Regulatory

N4 Pharma plc

 ("N4 Pharma" or the "Company")

N4 Pharma Launches New Interactive Investor Hub

Company to provide shareholders with a more proactive way of communication and enquiry support

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders, the new Investor Hub brings all N4 Pharma content into a single integrated platform to better inform and engage with investors and stakeholders, including:

●     regulatory announcements

●     annual and interim reports

●     corporate presentations

●     company information

●     interviews with the Company's directors

●     corporate research on N4 Pharma

Investor Hub also provides an interactive online experience allowing Company's stakeholders to comment on and ask the N4 Pharma team questions via a portal which will be monitored.

To sign up for the N4 Pharma Investor Hub:

1.    Visit investors.n4pharma.com.

2.    Follow the prompts to sign up for an investor hub account.

3.    Complete your account profile.

N4 Pharma's CEO and Founder, Nigel Theobald commented:

"At N4 Pharma, we have always encouraged our shareholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our shareholders, and potential shareholders to interact with N4 Pharma. Investor Hub will give us a platform to collate all our video material, information and insights about our activities and plans in one place. We encourage our stakeholders to trial Investor Hub and to provide feedback."

For more information please contact:

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.